Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART? by Powles, T et al.
Short Communication
Does HIV adversely influence the outcome in advanced
non-small-cell lung cancer in the era of HAART?
T Powles1, C Thirwell1, T Newsom-Davis1, M Nelson2, P Shah1, S Cox1, B Gazzard2 and M Bower*,1
1Department of Oncology, Chelsea & Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK; 2Department of HIV Medicine,
Chelsea & Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
The objectives of the study are to assess the impact of HIV status on the outcome of patients with non-small-cell lung cancer
(NSCLC) in the era of highly active antiretroviral therapy (HAART). Patients diagnosed with HIV-related NSCLC in the HAART era
(since January 1996) were identified from a prospective single-centre lung cancer database. The clinicopathological characteristics and
outcome of each HIV-positive patient were compared to three age- and stage-matched HIV-negative controls with NSCLC who
were diagnosed over the same time period and treated in an identical manner. The results showed that the two groups had similar
disease characteristics and received a similar amount of chemotherapy. The median overall survival of the two groups was the same
(4 months, log rank P¼ 0.55). None of the HIV-positive patients developed an AIDS defining illness or died of HIV during treatment
or follow-up. In conclusion, in this cohort, HIV status does not influence the prognosis of advanced NSCLC. This suggests that the
survival of patients with HIV-related NSCLC may have improved since the introduction of HAART, and this may be due to a
decrease in HIV-related deaths.
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HIV is associated with a small, but significant risk of developing
lung cancer; particularly non-small-cell lung cancer (NSCLC)
(Franceschi et al, 1998; Parker et al, 1998; Frisch et al, 2001).
Before the introduction of highly active antiretroviral therapy
(HAART), patients with HIV-related NSCLC had a worse outcome
compared to age-matched HIV-negative controls (Sridhar et al,
1992; Vyzula and Remick, 1996; Tirelli et al, 2000). It has been
suggested that this increased mortality was because the patients
were younger, and had both more advanced and more aggressive
disease compared to HIV-negative patients (Sridhar et al, 1992;
Vyzula and Remick, 1996; Whooley et al, 1999; Skarin et al, 2001).
Others have speculated that individuals with HIV-related lung
cancer were offered suboptimal treatment due to concerns
surrounding HIV-related comorbidity (Tirelli et al, 2000).
Since the introduction of HAART, the life expectancy of HIV
patients has increased (Palella et al, 1998). This is largely due to a
decrease in opportunistic infections; however, the outcome of a
number of HIV-related malignancies has also improved (Tam et al,
2002). Currently, there are no controlled data regarding the
outcome of patients with HIV-related lung cancer in the HAART
era, despite reports that the incidence of HIV-related lung cancer
may be rising (Bower et al, 2003).
In this study, we compare the treatment and outcome of HIV-
positive and age-matched HIV-negative controls with advanced
NSCLC in the HAART era.
PATIENTS AND METHODS
The clinical details of patients with HIV-related NSCLC, diagnosed
since the introduction of HAART in January 1996, were retrieved
from a prospective single-centre lung cancer database. The HIV-
negative control group was derived from the same database. For
each HIV-positive case patient, three HIV-negative controls were
identified who were of the same gender, had the same stage of lung
cancer and were within 6 years of age of the case patient.
All patients included had histologically confirmed lung cancer,
which for the cases was diagnosed after testing HIV seropositive.
Routine lung cancer staging was undertaken in all patients using
the American Joint Committee tumour-node-metastasis (TNM)
system. The HIV-positive and control groups were treated in an
identical manner using standard chemotherapy regimens (mito-
mycin, vincristine and cisplatin or gemcitabine and carboplatin,
depending on the date of diagnosis). None of the patients had
received prior chemotherapy or radiotherapy. The response to
treatment was evaluated using the RECIST guidelines (Therasse
et al, 2000) and toxicities were recorded according to the National
Cancer Institute common toxicity criteria (CTC) version 2.0.
Specifically age, date of cancer diagnosis, treatment, toxicity,
response to treatment and survival were recorded. Survival was
plotted according to the Kaplan–Meier method (Kaplan and
Meier, 1958).
RESULTS
Nine HIV-positive and 27 HIV-negative patients with NSCLC
were identified between January 1996 and October 2002. TheReceived 20 March 2003; accepted 1 May 2003
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HIV-positive patients and HIV-negative controls had similar
characteristics in terms of age, percent with stage IV disease and
proportion with adenocarcinoma. However, HIV-positive patients
appeared to have a worse performance status at presentation
(Tables 1 and 2). The HIV patients were relatively asymptomatic
with respect to their HIV disease, with a median CD4 cell count at
presentation of 160 mm3 (range 136–890 mm3), and a median
HIV viral load of 173 copies ml1 (range o50–200 000 copies
ml1). Three patients had no detectable HIV viraemia and four had
been diagnosed with an AIDS defining illness prior to the
development of lung cancer.
The median overall survival in both groups was 4 months (range
2–15þ months for HIV positives vs 1–24þ months for HIV
negatives). The 1-year survival for the HIV-positive patients was
11% compared to 22% for the HIV-negative group. The two groups
received a similar number of cycles of chemotherapy (Table 1).
Stable disease or a partial response was achieved in 50% of the
patients treated with chemotherapy in both the groups of patients.
Chemotherapy was stopped early in three HIV-positive patients,
two due to progression of disease and one due to chemotherapy
toxicity. In all, 50% of HIV-positive patients treated with
chemotherapy, developed grade 3 or 4 haematological toxicity;
however, there were no chemotherapy-related deaths. Seven
patients were on HAART at the start of treatment, two stopped
due to concern surrounding interaction of chemotherapy and
HAART. None of the HIV-positive patients developed an AIDS
defining diagnosis or died of HIV-related disease during treatment
or follow-up.
DISCUSSION
Non-small-cell lung cancer occurs more frequently in the HIV
population compared to HIV negatives (relative risk 4.5, 95%
Confidence Interval: 4.2–4.8) (Frisch et al, 2001). Moreover, it has
been reported that the incidence of NSCLC may be rising in people
with HIV (Bower et al, 2003). The reason for the link between these
two diseases is not clear; unlike most HIV-associated malignancies,
no viral oncogene has been implicated in NSCLC. It has been
speculated that the relationship is due to increased tobacco
exposure in the HIV-positive population (Parker et al, 1998). In
addition, pulmonary opportunistic infections and chronic immune
suppression have both been implicated in the disease process;
however, there is no clear consensus (Tirelli et al, 2000; Bower et al,
2003).
Before the introduction of HAART, HIV-related lung cancer
patients had a worse outcome than HIV-negative age-matched
controls (Sridhar et al, 1992; Vyzula and Remick, 1996; Tirelli et al,
2000) (Table 2). It was uncertain whether this was due to more
aggressive lung cancer (Sridhar et al, 1992; Vyzula and Remick,
1996) or diagnostic delays and suboptimal treatment compared to
HIV-negative controls (Tirelli et al, 2000). This controlled study
compares the outcome of these patients since the introduction of
HAART. It shows that the survival of the HIV-positive and HIV-
negative groups is now the same, suggesting that the outcome of
HIV-associated NSCLC has improved (Table 2, Figure 1). Since in
this study the groups were matched for NSCLC stage and the
treatment protocols used were the same in both the groups, the
results support the hypothesis that NSCLC is not more aggressive
in the immunocompromised. The prior reports of worse survival
in the HIV-positive patients may therefore have reflected excess
deaths due to immunodeficiency rather than NSCLC. Indeed, there
were fewer HIV-related deaths in this study compared to those in
the pre-HAART era (0 vs 16– 54%, respectively) (Hoffman et al,
2000; Tirelli et al, 2000) (Table 3). Moreover, in this study, HIV-
Table 1 Comparison of clinicopathological properties of cases (HIV+)
and controls (HIV)
HIV positive HIV negative
n 9 27
Median age 45 years 48 years
(range 32–58) (range 30–55)
Adenocarcinoma 66% 70%
Stage IV disease 66% 70%
ECOG performance status
o2 at presentation
22% 52%
(range 1–4) (range 1–4)
Treated with chemotherapy 88% 66%
Median number of cycles of
chemotherapy
3.5 4
(range 1–6) (range 1–6)
Median overall survival 4 months 4 months
(range 2–15+) (range 1–24+)
Cancer-related deaths 77% 74%
Table 2 HIV-positive patients with NSCLC
Age (Years) ECOG performance status Histology Stage Site of metastasis Treatment Response Survival (months)
1 50 3 Squamous IV Bone Chemotherapy PD 2
2 58 2 Adeno IV Bone Palliative 2
3 44 1 Squamous IIIB Chemotherapy PR 5
4 48 4 Squamous IV Brain Chemotherapy PR 5
5 57 4 Adeno IIIB Chemotherapy PR 3
6 45 1 Adeno IIIB Chemotherapy PR 15+
7 43 3 Adeno IV Bone Chemotherapy PD 2
8 32 2 Adeno IIIB Chemotherapy SD 8
9 43 2 Adeno IV Bone Chemotherapy SD 7
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Figure 1 Kaplan–Meier overall survival duration curve from diagnosis of
lung cancer according to HIV serostatus.
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positive and -negative patients received equivalent amounts of
chemotherapy. This does not appear to be the case for patients in
the pre-HAART era, where dose modifications were common
(Sridhar et al, 1992; Hoffman et al, 2000). These two factors may
help explain the improved outcome of patients in this study.
Three of the four studies in the pre-HAART era were not well
controlled. Two had a significantly older HIV-negative cohort
(Hoffman et al, 2000; Tirelli et al, 2000), while the other was not
matched for stage of disease (Vyzula and Remick, 1996). It may be
that these confounding factors biased the results in favour of HIV
negatives; however, there was a high degree of significance in all
four studies (see Table 2). It has also been speculated that a smaller
proportion of HIV patients with operable disease are offered
surgery, resulting in worse outcome (Tirelli et al, 2000). This issue
remains unresolved, as all of the patients in this study had
advanced disease. The HIV-positive and -negative groups present
in this study were remarkably similar, with a similar median age,
proportion with adenocarcinoma and a similar amount of
chemotherapy given. The HIV-positive patients did appear to
have a poorer performance status than the negative group, which is
associated with a worse outcome (Schiller et al, 2002).
Advanced HIV-related NSCLC is still associated with a poor
outcome in the HAART era (median survival 4 months). However,
this may reflect the advanced and aggressive nature of the disease
in young people as a whole, rather than exclusively in people with
HIV. It has been speculated that the high proportion of
adenocarcinomas in the young, which is associated with early
metastasis, may be responsible for this poor survival (Hoffman
et al, 2000). There are no specific data on the median survival of
patients with advanced NSCLC pre-HAART era; however, despite
being incomplete, pooled data give a figure of approximately 2
months (n¼ 23) (Sridhar et al, 1992; Vyzula and Remick, 1996;
Alshafie et al, 1997).
It is of note that two of the patients in this study stopped
HAART during or at the time of chemotherapy. The continuation
of HAART is thought to reduce opportunistic infections and
preserve immune parameters (Powles et al, 2002; Bower et al,
2003). However, if interactions between chemotherapy and
HAART do occur, it may be worth considering a modification of
the antiretroviral regimen rather than stopping the chemotherapy,
as long-term prevention of HIV progression may be less of a
priority in view of the poor prognosis of these patients.
Prophylaxis against opportunistic infection is therefore crucial in
this setting.
The data presented here suggest that the introduction of HAART
may have improved outcome in advanced NSCLC in HIV-positive
individuals. This may be due to decreased HIV-related mortality
and an increased ability to tolerate treatment. These individuals
may now have a similar outcome to HIV-negative people with the
disease, provided that they are treated in a similar manner.
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